Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
REDWOOD CITY, Calif., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a developer of innovative treatments for peripheral artery disease (PAD), today announced the company has...
-
MILLWOOD, Va., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Project HOPE and Boeing are teaming up to significantly improve pediatric, neonatal and maternity care in Papa, Hungary, through the expansion of a...
-
CRANBURY, N.J., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced...
-
DEERFIELD, Ill., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Surgical Care Affiliates, Inc. (NASDAQ:SCAI) (“SCA”), a leader in the outpatient surgery industry, has partnered with Executive Surgery Center...
-
BOSTON, Sept. 13, 2016 (GLOBE NEWSWIRE) -- The National Patient Safety Foundation's Lucian Leape Institute has announced the appointment of Sue Sheridan, MBA, MIM, DHL, as a member, effective...
-
ARLINGTON, Va., Sept. 13, 2016 (GLOBE NEWSWIRE) -- To help employees gain needed insight during the upcoming open enrollment season, Willis Towers Watson (NASDAQ:WLTW), a leading global advisory,...
-
DELRAY BEACH, Fla., Sept. 13, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced...
-
Broomfield, CO, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, has entered into definitive...
-
Ocean View, Delaware, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Cancer Gene Therapy Market size was USD 805.5 million in 2015, with 20.7% CAGR estimation from 2016 to 2024; as per a new research report...
-
Preclinical study of RGX-111 for the treatment of Mucopolysaccharidosis Type I (MPS I) demonstrates disease correction from a single administration of NAV AAV9 in a canine model; expected to help...